Atherosclerosis
Sort by:
American Heart & Vascular Institute
Icosapent Ethyl for Patients With HTG: A New Paradigm in CVD Prevention
FEATURING
Eliot Brinton
- 245 views
- April 8, 2021
Philips
A Message to Healthcare providers around PAD and PVD
FEATURING
Foluso Fakorede
- 132 views
- April 7, 2021
American Heart & Vascular Institute
Limb Salvage in PAD: What Are the Available Technologies/Techniques?
FEATURING
Aaron Frodsham
- 416 views
- April 1, 2021
Houston Methodist DeBakey Heart and Vascular Center
Developments in Positron Emission Tomography for Diagnosis and Management of CAD
FEATURING
Marcelo Carli
- 108 views
- March 26, 2021
Houston Methodist DeBakey Heart and Vascular Center
Predicting Progression of CVD and Cognitive Dysfunction in Childhood, Midlife and Elderly: When and Where Does the Atherosclerosis Start? How to Use Multimodality Imaging to Predict Plaque Progression?
FEATURING
Valentin Fuster
- 325 views
- March 26, 2021
- 2
ASPC 2020 Virtual Summit on CVD Prevention
Integrating Imaging & Advanced Blood Testing for CVD Prevention/Management: How Do We Know If the Patient Is in Prediabetes Phase? Why Do Lipoproteins Become Atherogenic? What Is the Role of Non-Lifestyle Genetic Markers?
FEATURING
Arthur Agatston
- 483 views
- March 24, 2021
- 3
ASPC 2020 Virtual Summit on CVD Prevention
ASPC CVD Prevention Panel Discussion: How Can We Educate Our Patients to Prevent CVD? What Happens With Atherosclerotic Plaque/Calcium Density in Menopause? How to Diagnose CMD When We Don’t Have All Available Technologies?
FEATURING
Leslee Shaw,
Nanette Wenger,
Viviany Taqueti,
Renee Bullock-Palmer,
Erin Michos,
Martha Gulati,
Pam Taub
- 18 views
- March 17, 2021
ASPC 2020 Virtual Summit on CVD Prevention
Atherosclerosis & MicroRNAs: How MicroRNAs Impacts Risk for Atherogenesis?
FEATURING
Peter Toth
- 94 views
- March 16, 2021
- 1
ASPC 2020 Virtual Summit on CVD Prevention
Primary Prevention by CAC vs. CTA: Which One Is Better and Why? - SCCT Expert Debate
FEATURING
James Min,
Khurram Nasir
- 39 views
- March 16, 2021
ASPC 2020 Virtual Summit on CVD Prevention
Discussion on CTA/CAC for Primary Prevention, Genetic Testing, LDL Mutations, and Implementation of FIND FH Into Clinical Care - 2020 ASPC Virtual Summit on CVD Prevention
FEATURING
Ron Blankstein,
Salim Virani,
Arthur Agatston,
James Min,
Samip Sheth,
Khurram Nasir,
Amit Khera
- 24 views
- March 16, 2021
Keck School of Medicine of USC
Role of Lipoprotein(a) in Coronary Disease: What CV Risks Can you Expect? How to Manage the Condition?
FEATURING
Steven Nissen
- 947 views
- January 5, 2021
- 13
Matthew Budoff
LDL Lowering and CV Risk: What to Consider When Working to Reduce Patients' LDL Cholesterol?
- 256 views
- December 3, 2020
- 1
Cardiometabolic Health Congress (CMHC)
Q&A on Novel Therapies and Approaches in LDL-C Reduction
- 605 views
- September 22, 2020
Cardiometabolic Health Congress (CMHC)
2020 Update on Lipid Lowering Therapy in ASCD: What Medications Are Available to Address Residual Risk of in Statin Treated Patients? What Do the Treatment Guidelines Define as High-Risk Patients in Primary Prevention?
FEATURING
Salim Virani
- 898 views
- September 22, 2020
- 3
Houston Methodist DeBakey Heart and Vascular Center
Update on Inflammation & Atherosclerosis Treatment: Should All Atherosclerosis Patients Receive Aggressive Lipid-Lowering and Inflammation Inhibiting Therapy? Why Not Combine Anti-Inflammatory Therapy with PCSK9 Inhibition?
FEATURING
Paul Ridker
- 1,523 views
- July 14, 2020
- 9
